Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Inclusion Criteria * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Patients must have the ability to swallow oral medication. * Patients must have resected adenocarcinoma of the colon staged as American Joint Committee on Cancer (AJCC) Stage 0, I, II, or III. * Patients must have had surgical resection of the colon adenocarcinoma with curative intent within 1 year prior to randomization. (Laparoscopically-assisted colectomy is permitted.) * Patients must have completed any adjuvant therapy prior to randomization. * Patients who are taking cardioprotective low-dose aspirin at study entry must not have clinically significant toxicity, as determined by the investigator, that precludes continuation of aspirin, and the patient must be willing to continue aspirin therapy (81 mg or 325 mg) throughout study therapy. * Colonoscopy requirements within 180 days prior to randomization: * The patient must have either undergone a preoperative or postoperative documented colonoscopy to the cecum (or small bowel anastomosis) with adequate bowel preparation. * All observed polyps must have been removed. (Polyps can be removed during colonoscopy or surgery performed prior to randomization.) * Postoperative serum creatinine performed within 90 days prior to randomization must be less than or equal to 1.5 x upper limit of normal (ULN) for the lab. * The following criteria for evidence of adequate hepatic function based on postoperative testing p…